• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Theobromine and its derivatives for the treatment or prevention of renal lithiasis. The present invention relates to the use of theobromine or its derivatives as an inhibitor of the crystallization of uric acid to prevent the formation of uric acid crystals in urine and, as a consequence, renal lithiasis or, in particular, uric kidney lithiasis. (Machine-translation by Google Translate, not legally binding)
    公开号:ES2552706A1
    申请号:ES201430819
    申请日:2014-05-29
    公开日:2015-12-01
    发明作者:Félix Grases Freixedas；Antonia COSTA BAUZÁ；Rafael Maria Prieto Almirall；Adrian RODRÍGUEZ RODRÍGUEZ
    申请人:Universitat de les Illes Balears；
    IPC主号:
    专利说明:

    The present invention relates to the use of theobromine or its derivatives as an inhibitor of uric acid crystallization to prevent the formation of uric acid crystals in urine and as a consequence uric renal lithiasis.
    STATE OF THE TECHNIQUE
    At present it is known that the fundamental problem of uric renal lithiasis lies in the more or less persistent existence of urinary pH values below 5.5. Urinary supersaturation of uric acid linked to the excretion of this substance is important, but in virtually no case has it been shown to be a decisive factor in the development of lithiasis. It is intuited that the presence of inhibitors of uric acid crystallization may be relevant, since individuals with the same urinary pH values and uric acid concentration, some form uric kidney stones and others do not. However, although there has been some "in vitro" study of potential inhibitors of uric acid crystallization, where it has been shown that saponins, glycosaminoglycans and glycoproteins exhibit a remarkable ability to inhibit uric acid crystallization, no known clinical study on this subject.
    Currently, the prophylactic treatment of uric kidney stones is based on the implementation of dietary measures to decrease uric acid levels in the urine and in turn increase urinary pH levels. For this reason it is recommended to reduce the excessive consumption of protein of animal origin (red meat, seafood, blue fish, viscera, etc.) and alcoholic beverages and increase the consumption of fruits (mainly citrus) and vegetables, as well as carbonated beverages. The only drugs currently used for the treatment of uric renal lithiasis are citrate as a urinary basifying agent and, in those cases in which hyperuricemia is detected, plasma uric synthesis is decreased through the inhibition of Xanthine oxidase enzyme, responsible for the synthesis of uric acid,
    by oral administration of allopurinol or febuxostat (Grases F et aL, Urol. Int. 1999; 62 (4): 201-4; Ngo Te, et al., Rev. Urol. 2007; 9 (1): 17-27) .
    Therefore the therapeutic arsenal available for the treatment of uric lithiasis is still very limited, being of interest the contribution of new therapeutic strategies that provide new solutions to this pathology.
    DESCRIPTION OF THE INVENTION
    The present invention aims to present a new product for the treatment of renal uric acid lithiasis based on the discovery of a new and potent inhibitor of uric acid crystallization. Said product will be a derivative of xanthine, modifying positions 3 and 7 by a linear or branched chain of alkyl groups of one to six carbon atoms and which may be the same or different
    15 each other. For example, with groups R1 and R2 as methyl groups, a dimethylxanthine called theobromine.
    Theobromine (C7HsN40 2, chemical name 3,7-dimethylxanthine or 3,7-dihydro-3,7dimethyl-1H-purine-2,6-dione) is an alkaloid of the methylxanthine family, family
    20 which also includes theophylline and caffeine. Unlike caffeine, theobromine has two methyl groups instead of three.
    Therefore, a first aspect of the present invention relates to the use of a compound of general formula (1)
    or
    (1) where: R, and R2 are the same or different and represent an alkyl group (e 1 -Ce) or any of its pharmaceutically acceptable salts for the preparation of a
    Composition for the treatment and / or prevention of renal lithiasis, preferably uric renal lithiasis.
    The term "alkyl" refers, in the present invention, to saturated, linear or branched hydrocarbon chains having 1 to 6 carbon atoms, for example, methyl, ethyl, n-propyl, i-propyl, n-butyl , tere-butyl, see-butyl, n-pentyl, n-hexyl, etc., more preferably from 1 to 3 carbon atoms and more preferably is a methyl.
    In a preferred embodiment, R 1 is a (C 1 -C 3) alkyl group, more preferably R 1 is a methyl.
    In another preferred embodiment R2 is a (C, -C3) alkyl group, more preferably R2 is
    a methyl
    In a more preferred embodiment, R1 and R2 are a methyl group.
    Taking into account that it has been demonstrated in the present invention that the compounds of general formula (1) are inhibitors of uric acid crystallization, in another particular embodiment, the compound of formula (1) as described above is used for development of a composition aimed at reducing risks and improving the health status of patients with diseases related to uric acid crystallization, such as uric kidney stones.
    Theobromine is found in fairly high concentrations in chocolate. A 50g piece of dark or dark chocolate, which contains a minimum of 34% to a maximum of 98% cocoa, may contain an average of 378 mg of theobromine. This amount of chocolate is obviously safe and can be consumed without any side effects. Doses of more than 1000 mg have been used safely in clinical trials without side or toxic effects, but may cause mild stomach discomfort. A large amount of cocoa must be ingested so that theobromine can have harmful effects on humans. Although theobromine does not cause harmful effects to humans, it is highly toxic to some pets, including dogs and cats. A low dose of
    Theobromine in animals, can cause cardiac arrhythmias and seizures, and even death.
    Therefore, in a preferred embodiment the present invention relates to the use of a
    Preparation of a compound of formula (1), more preferably of theobromine, forits use in a composition (pharmaceutical, nutraceutical, food compositionfunctional or dietary supplement) for the treatment or prevention of renal lithiasis,preferably uric. The doses used range from 100 mg / day to 380 mg / day.
    10 The term "renal lithiasis", "urolithiasis" or "nephrolithiasis" refers to the disorder caused by the presence of stones or stones inside the kidneys or urinary tract (ureters, bladder). Kidney stones are made up of normal urine substances (calcium salts, uric acid, cystine etc.) that for different reasons have been concentrated and precipitated forming fragments of greater or lesser size.
    The term "uric acid crystals" or "uric acid stones" includes all that
    process or conditions that involve / induce the formation of solid precipitates in the
    urine in which this substance is involved
    In a preferred embodiment, the composition is a pharmaceutical composition or a nutraceutical or functional food.
    In the present invention it is understood as "nutraceutical" or "functional food", a food that has a beneficial effect on health. Similarly, the term
    Nutraceutical can be applied to extracts or chemical compounds obtained from common foods. Examples of foods to which nutraceutical properties are attributed are olive oil, red wine, broccoli, soybeans, etc. Nutraceuticals are normally used in nutritional mixtures and in the pharmaceutical industry. In the same way that some foods can be classified as
    30 nutraceuticals are also classified in this way to some nutritional supplements, such as fatty acids such as omega-3 derived from fish oil and some vegetables or antioxidants and vitamins.
    The compound of formula (I), and in particular theobromine, can be administered in solid form (including granules, powder or suppositories) or in liquid form (such as solutions, suspensions or emulsions). In turn, they can be administered as such or, after being subjected to operations such as sterilization, addition
    5 of preservatives, addition of stabilizers or addition of emulsifiers.
    Administration of the compound of formula (1), in particular of theobromine, may
    combine with one or more compounds that facilitate its absorption through the route
    of selected administration. Thus, they can be administered with lactose, sucrose,
    10 talc, magnesium stearate, cellulose, calcium salts, gelatin, fatty acids, as well as other similar substances.
    The pharmaceutically acceptable adjuvants and vehicles that can be used in said compositions are the adjuvants and vehicles known to those skilled in the art and commonly used in the elaboration of therapeutic compositions.
    For application in therapy, the compound of formula (1), in particular theobromine, will preferably be in a pharmaceutically acceptable or substantially pure form, that is, it has a pharmaceutically acceptable level of purity excluding normal pharmaceutical additives. such as diluents and carriers, and not including material considered toxic at normal dosage levels. The purity levels for the active ingredient are preferably greater than 50%, more preferably greater than 70%, and even more
    25 preferably greater than 90%. In a preferred embodiment, they are greater than 95% of the compound of formula (1), or of its salts or solvates.
    Throughout the description and claims the word "comprises" and its variants are not intended to exclude other technical characteristics, additives, components or
    30 steps For those skilled in the art, other objects, advantages and features of the invention will be derived partly from the description and partly from the practice of the invention. The following examples and figure are provided by way of illustration, and are not intended to be limiting of the present invention.
    BRIEF DESCRIPTION OF THE FIGURES
    FIG. 1. Kinetic curves for crystallization of uric acid (400 mg / L) in synthetic urine at pH = 4.67, at different concentrations of theobromine. The absorbance (at 550 nm) is plotted against time (in minutes).
    FIG. 2. Graphical representation of the induction periods (in minutes), for a solution of 400 mg / L of uric acid in synthetic urine, at different pH values and theobromine concentration.
    FIG. 3. Uric acid crystals, observed by scanning electron microscopy, obtained in synthetic urine at pH = 4.67 in the absence of theobromine (A) and in the presence of 20 mg / L (B) and 40 mg / L (e) of theobromine .
    FIG. 4. Scheme of the flow system used, consisting of a solution of synthetic urine, a solution of uric acid both driven by two peristaltic pumps at different flow rates, a T-shaped connection and a chamber containing the calculation of uric acid
    FIG. 5. Mass increase percentage (with standard error bar) in Vitro of uric acid kidney stone fragments from the same patient, obtained after extracorporeal shock wave lithotripsy, when subjected to a constant flow of synthetic urine for 48 hours in the presence of different concentrations of theobromine.
    FIG. 6. Fragments of uric acid kidney stones observed by scanning electron microscopy, which have grown in contact with synthetic urine, without theobromine (A) and with 20 mg / L of theobromine (B).
    EXAMPLES
    From a solution of 400 mg / L of uric acid in synthetic urine (of medium composition similar to urine), and at different pH and concentrations of theobromine, the corresponding kinetic cUlVas of crystallization of uric acid were recorded with a turbidimeter. FIG. 1 shows the kinetic curves for uric acid (without theobromine), and for that same concentration of uric acid by adding 10, 20, and 40 mg / L of theobromine, at pH = 4.67. As can be seen, the induction time (time at which crystals begin to appear) increases markedly as
    5 we increase the concentration of theobromine, which indicates that this substanceIt acts as an inhibitor of uric acid nucleation.
    Thus, induction times were calculated for 400 mg / L of uric acid in synthetic urine, at different pH and different concentrations of theobromine (table 2). So and
    10 as can be seen graphically in FIG. 2, induction times increase with increasing theobromine concentration. In addition, this inhibitory effect is much more pronounced when urinary pH is increased.
    Table 1. Induction times (and standard deviation (SD)) for a solution of
    15 400 mg / L of uric acid in synthetic urine at different pH and concentrations of theobromine.
    Conob. Theobromine (mg / L) Induction time (min)FROM
    pH = 4.39 OR2.30.07
    10 4.30.4
    twenty 6.8OR
    40 fifteen2.8
    pH = 4, SO OR3OR
    10 3.90.5
    twenty 6.90.14
    40 14.8one
    pH = 4.67 OR60.6
    10 133
    twenty 2. 33
    40 384
    The precipitate generated during the turbidimetric experiment was filtered under vacuum, the crystals were allowed to dry, and looked through a scanning electron microscope to see if there was a difference in the morphology of the crystals as a function of the theobromine concentration. FIG. 3 shows said crystals generated from a solution of 400 mglL in synthetic urine at pH = 4.67, without theobromine, and with 20 and 40 mg / L of theobromine. As can be seen, as the theobromine concentration increases, the morphology of the uric acid crystals changes, becoming much narrower and elongated. This means that the inhibitor acts on the lateral faces of the crystal, preventing it from growing in that area. Thus, in addition to being an inhibitor of uric acid nucleation, it also acts as an inhibitor of crystalline growth.
    The last experiment that was performed was a study of the effect of theobromine as an inhibitor of uric acid crystalline growth. For this, fragments of uric acid stones from the same patient (obtained by extracorporeal shock wave lithotripsy) were used, which were passed synthetic urine with 400 mg / L of uric acid and different concentrations of theobromine, by a system in flow like the one represented in FIG. 4. This system consists of two peristaltic pumps. One of them drives synthetic urine without uric acid at pH = 3.00 (4-A). The other one drives a 2 gIL uric acid solution at pH = 10.70 (4-8). Both solutions were thermostated at 37 ° C (5). When it was wanted to study the effect of theobromine, it dissolved in synthetic urine. Said solutions (synthetic urine and uric acid) are mixed in the T-shaped connection (3), and synthetic urine is produced at 400 mg / l uric acid, at a pH of around 5.40. Peristaltic pumps have different flow rates, taking into account that the final synthetic urine must have 400 mg / L of uric acid, and that the total volume over a day should be 750 mL, which is the average volume of urine that passes for a kidney
    Once the solutions of uric acid and synthetic urine are mixed, it passes through a chamber inside the oven at 3rC (1) containing a calculation of previously weighed uric acid (2). The flow system is maintained for 48 hours. When finished, the calculations are dried in a stove, and they are weighed again. Thus, the mass increase% is calculated.
    FIG. 5 shows the percentage of mass increase as a function of the theobromine concentration. Five calculations were used for each concentration of theobromine. As can be seen, as the theobromine concentration increases, the mass% of the stone fragments decreases, the increase being practically
    5 null at 20 mg / L of theobromine.
    To see if there was a difference in the morphology of the calculation based on the concentration
    of theobromine after the stones were submitted to the flow process, two were taken
    scanning electron microscope fragments (FIG. 6). It can be seen that, when not
    10 there is an inhibitor, the fragments that have grown on the surface of the stone are larger than when there was theobromine.
    All previous experiments show a high capacity of theobromine to inhibit both nucleation and crystalline growth of the acid.
    15 uric, with a potential application in the treatment and prevention of renal lithiasis.
    权利要求:
    Claims (8)
    [1]
    1. Use of a compound of general formula (1) OR
    5 (1)
    where: R1 and R2 are the same or different and represent an alkyl group (er e6) or any of its pharmaceutically acceptable salts for the preparation of a composition for the treatment and / or prevention of renal lithiasis.
    Use according to claim 1, wherein R, is an alkyl group (e, -e)).
    [3]
    3. Use according to claim 2, wherein R is a methyl.
    [4]
    Four. Use according to any one of claims 1 to 3, wherein Rz is an alkyl group (C, -C,).
    [5]
    5. Use according to claim 4, wherein R2 is a methyl.
    [6]
    6. Use according to any one of claims 1 to 5, wherein R, and Rz are a methyl group.
    [7]
    7. Use according to any of claims 1 to 6, wherein the renal lithiasis is uric renal lithiasis.
    Use of the compound of general formula (1) described in any of claims 1 to 6, for the preparation of a composition intended to reduce risks and improve the health status of patients with diseases related to uric acid crystallization.
    [9]
    9. Use according to any one of claims 1 to 8, wherein the composition is a pharmaceutical composition, functional food, a nutraceutical product or a food supplement.
    [10]
    10. Use according to any of claims 1 to 9, wherein the compound of general formula (1) is in a dose suitable for administration between 100 mg / day and 380 mg / day.
    Use according to any one of claims 1 to 10, wherein the composition in addition to a compound of formula (1) comprises lactose, sucrose, talc, magnesium stearate, cellulose, calcium salts, gelatin or fatty acids.
    类似技术:
    公开号 | 公开日 | 专利标题
    JP5788527B2|2015-09-30|Side effects reducing agent of kinase inhibitor
    US20200282024A1|2020-09-10|Formulations for compound delivery
    ES2552706B1|2016-09-13|THEOBOBROMINE AND ITS DERIVATIVES FOR THE TREATMENT OR PREVENTION OF RENAL LITHIASIS
    WO2015097231A9|2015-12-10|Prodrugs of urolithins and uses thereof
    WO2020253835A1|2020-12-24|Nitrate and vitamin-containing composition, preparation method therefor, formulation thereof and use thereof
    ES2401754T3|2013-04-24|Compositions containing apoacuorin and methods of use thereof
    JP6979427B2|2021-12-15|High-concentration formulation of soluble Fc receptor
    ES2668525T3|2018-05-18|Antihypoxic pharmaceutical composition and its application
    WO2016163082A1|2016-10-13|Prophylactic/therapeutic agent for virus infections which comprises ala compound
    WO2009041798A1|2009-04-02|Pharmaceutical compositions combining a nonsteroidal anti-inflammatory agent and a xanthine oxidase inhibiting agent, which can be used to control and treat gout, gouty arthritis and related diseases
    KR101751420B1|2017-06-27|Pharmaceutical Composition comprising a Compound extracted from Phellinus Linteus for treating or preventing Gastric Ulcers
    WO2015150608A1|2015-10-08|Combination of a urinary acidifier and a calcium phosphate crystallisation inhibitor for the treatment or prevention of renal lithiasis
    ES2729863T3|2019-11-06|Combinations of a urinary basifying agent and a uric acid crystallization inhibitor for the treatment or prevention of renal lithiasis
    US10945975B2|2021-03-16|Delaying latency to seizure by combinations of ketone supplements
    WO2016139740A1|2016-09-09|Hepatic fibrosis-ameliorating agent
    KR101890870B1|2018-08-22|A compositon for preventing, alleviating or treating rheumatoid arthritis comprising alpha-iso-cubebene or pharmaceutically acceptable salts thereof
    KR101913326B1|2018-10-30|Pharmaceutical composition for preventing or treating renal ischemia reperfusion injury comprising cilastatin
    KR101890858B1|2018-08-22|A compositon for preventing, alleviating or treating rheumatoid arthritis comprising alpha-iso-cubebenol or pharmaceutically acceptable salts thereof
    CA2658314A1|2008-01-31|Parenteral preparations of gi-safer phospholipid-associated anti-inflammatories and methods of preparation and use
    JP2008031054A|2008-02-14|Immunomodulatory agent
    El-Saleh2006|Protection by Natural Honey Against Hyperhomocysteinemia in Rats
    JP2011157339A|2011-08-18|Pharmaceutical composition and health food by special method for production | in which absorbability is increased and efficacy and effect are enhanced during internal use of saponin-containing crude drug, including ginseng
    Shore-Lesserson et al.2004|Clopidogrel induces a platelet aggregation defect that is partially mitigated by ex-vivo addition of aprotinin
    US20150038547A1|2015-02-05|Biological Basis of Adult Wellness
    WO2003006032A1|2003-01-23|Pharmaceutical preparations for treatment or prophylaxis of arthritis urica
    同族专利:
    公开号 | 公开日
    ES2552706B1|2016-09-13|
    EP3150208A1|2017-04-05|
    CN106456646B|2020-03-27|
    CN106456646A|2017-02-22|
    JP6661551B2|2020-03-11|
    MX2016015577A|2018-03-01|
    JP2017516791A|2017-06-22|
    WO2015181412A1|2015-12-03|
    CA2950036A1|2015-12-03|
    US10149851B2|2018-12-11|
    US20170143724A1|2017-05-25|
    KR20170005020A|2017-01-11|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3624205A|1967-04-25|1971-11-30|Burroughs Wellcome Co|Treatment of hyperuricemia in humans|
    GB2284761A|1993-12-03|1995-06-21|Euro Celtique Sa|Prophylactic treatment of asthma|
    HU9700654A2|1997-03-26|1999-09-28|Dezső Korbonits|Antitussive compositions containing theobromine|
    GB0719544D0|2007-10-08|2007-11-14|Barry Callebaut Ag|Cocoa extract and use thereof|
    WO2011144545A1|2010-05-19|2011-11-24|Unilever Nv|Theobromine for increasing hdl-cholesterol|
    KR101797936B1|2010-09-10|2017-11-15|다케다 파마슈티칼스 유에스에이, 인코포레이티드|Methods for concomitant treatment of theophylline and febuxostat|EP3397640B1|2015-12-29|2021-08-04|INSERM - Institut National de la Santé et de la Recherche Médicale|Xanthine derivative inhibitors of bet proteins|
    ES2728434B2|2018-04-20|2020-02-24|Univ Illes Balears|Xanthine Crystallization Inhibitors|
    法律状态:
    2016-09-13| FG2A| Definitive protection|Ref document number: 2552706 Country of ref document: ES Kind code of ref document: B1 Effective date: 20160913 |
    优先权:
    申请号 | 申请日 | 专利标题
    ES201430819A|ES2552706B1|2014-05-29|2014-05-29|THEOBOBROMINE AND ITS DERIVATIVES FOR THE TREATMENT OR PREVENTION OF RENAL LITHIASIS|ES201430819A| ES2552706B1|2014-05-29|2014-05-29|THEOBOBROMINE AND ITS DERIVATIVES FOR THE TREATMENT OR PREVENTION OF RENAL LITHIASIS|
    KR1020167032807A| KR20170005020A|2014-05-29|2015-04-15|Theobromine or its derivatives for the treatment or prevention of renal lithiasis|
    MX2016015577A| MX2016015577A|2014-05-29|2015-04-15|Theobromine or its derivatives for the treatment or prevention of renal lithiasis.|
    CA2950036A| CA2950036A1|2014-05-29|2015-04-15|Theobromine or its derivatives for the treatment or prevention of renal lithiasis|
    US15/313,269| US10149851B2|2014-05-29|2015-04-15|Theobromine or its derivatives for the treatment or prevention of renal lithiasis|
    CN201580026766.XA| CN106456646B|2014-05-29|2015-04-15|Theobromine or its derivatives for treating or preventing nephrolithiasis|
    EP15724334.6A| EP3150208A1|2014-05-29|2015-04-15|Theobromine or its derivatives for the treatment or prevention of renal lithiasis|
    PCT/ES2015/070301| WO2015181412A1|2014-05-29|2015-04-15|Theobromine or its derivatives for the treatment or prevention of renal lithiasis|
    JP2016569697A| JP6661551B2|2014-05-29|2015-04-15|Theobromine or a derivative thereof for treating or preventing uric acid nephrolithiasis|
    [返回顶部]